Keyword: Takeda

Though the top prize eluded the field, 10 pharma companies racked up gold, silver or bronze Lions for their marketing and advertising efforts.

FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.

Takeda shareholders who oppose the company’s $62 billion buyout of Shire are gaining support for their effort to block the deal.

We're bringing you some of our favorite conversation snippets that capture the joy, fear and “ho hum” moments that come with running a cancer drugmaker.

Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.

Takeda's loss of market value is being cited by a group of 12 shareholders stepping up to oppose its acquisition of Shire.

J&J, Roche and Pfizer are most flexible in making M&A deals, but AstraZeneca might not be an easy target, a Leerink report shows.

Astellas plots 600 job cuts in Japan; GSK's infectious disease lead launches a Chinese biotech; Sun Pharma's Zytiga rival wins the FDA's blessing.

Roche's Hemlibra, on its way to treating a much wider population, put up some big data over the weekend that should back its bid at FDA.

China's WuXi Biologics and Sinobioway will build biologics facilities; Takeda expects Velcade freefall and looks to offload R&D assets to cut costs.